Matthew Bhatt

Matthew Bhatt investigates checkpoint immunotherapy for urothelial bladder cancer including cisplatin-ineligible patients with limited chemotherapy options. His research has contributed to clinical evaluation of pembrolizumab and atezolizumab in platinum-refractory and cisplatin-ineligible advanced urothelial carcinoma, where these agents achieved FDA approvals. He has characterized biomarkers predicting immunotherapy benefit in urothelial carcinoma including FGFR3 mutation status, tumor mutational burden, and immune cell infiltration patterns. His translational work on neoadjuvant immunotherapy in muscle-invasive bladder cancer explores whether checkpoint blockade before cystectomy can improve pathological complete response rates and long-term outcomes.